Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Employees

Sector

Biotechnology & Medical Research

More about the company

26/08	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
12/08	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI

Market Cap	54.37M 39.12M 33.66M 31.59M 28.9M 53.94M 3.7B 374M 146M 1.89B 147M 144M 6.09B	P/E 2026 *	-2.03x	P/E 2027 *	-2.19x
Enterprise Value	54.37M 39.12M 33.66M 31.59M 28.9M 53.94M 3.7B 374M 146M 1.89B 147M 144M 6.09B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	87.66%	Yield 2026 *	-	Yield 2027 *	-

26/08	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
12/08	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI
24/07	Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea	CI
25/06	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
25/06	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT
15/05	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI
15/05	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
15/05	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea	RE
15/05	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea	CI
22/04	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints	CI
27/03	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position	RE
26/03	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation	CI
17/03	Incannex regains compliance with Nasdaq minimum bid price requirement	RE

25/08	Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X	AQ
11/08	Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026	AQ
23/07	Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea	AQ
25/06	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ
10/06	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility	AQ

Manager	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	37	01/01/2016
Joseph Swan DFI	Director of Finance/CFO	35	29/02/2024
Luigi Barbato CTO	Chief Tech/Sci/R&D Officer	63	21/10/2024

Mount Magnet South Ltd Stock Australian S.E.

Stocks

AU000000MUM1

Biotechnology & Medical Research

Valuation : Mount Magnet South Ltd

Latest news : Mount Magnet South Ltd

Analysts' recommendations : Mount Magnet South Ltd

Press Releases : Mount Magnet South Ltd

Managers and Directors : Mount Magnet South Ltd

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Troy Valentine CHM	Chairman	52	01/11/2023
Peter Widdows BRD	Director/Board Member	60	01/11/2023
Joel Latham BRD	Director/Board Member	37	01/01/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.41%	-1.65%	+39.85%	+95.40%	68.87B
ARGENX SE	+1.31%	+1.65%	+50.56%	+90.80%	65.29B
INSMED INCORPORATED	+0.04%	+1.84%	-12.81%	+459.54%	27.65B
WUXI BIOLOGICS (CAYMAN) INC.	+2.97%	-0.10%	+41.86%	+14.84%	25.77B
BIONTECH SE	-0.90%	-8.60%	+2.25%	-15.50%	26.08B
GENMAB A/S	+1.01%	+1.76%	+32.99%	-17.16%	20.14B
PHARMAESSENTIA CORPORATION	+3.45%	-14.83%	+225.22%	+389.50%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-4.55%	-0.36%	+549.41%	15.03B
EXELIXIS, INC.	+1.03%	+5.40%	+59.04%	+160.03%	14.5B
Average	+1.06%	-2.44%	+48.73%	+191.87%	31.15B
Weighted average by Cap.	+0.92%	-1.63%	+43.44%	+149.98%

	2026 *	2027 *
Net sales	-	-
Net income	-24.91M -17.93M -15.43M -14.48M -13.24M -24.72M -1.69B -171M -66.69M -866M -67.32M -65.86M -2.79B	-24.89M -17.91M -15.41M -14.46M -13.23M -24.69M -1.69B -171M -66.61M -865M -67.25M -65.78M -2.79B
Net Debt	-	-

End-of-day quote Australian S.E.
- ^AUD	-